Xconomy National

Archives

by in

Entry	Author	Date	Location
Stealthy Mercator, Founded by Biogen Idec Veterans, Raises $2M to Attack Cancer	Ryan McBride	08/11/10	Boston
Achaogen, Flush with $56M, Seeks to Build Lasting Company with Potent Antibiotics	Luke Timmerman	07/19/10	San Francisco
Biogen Idec Reaches Deal With Icahn, Ironwood CEO Shares IPO Strategy, Luke Maps out the Genetics Institute Diaspora, & More Boston-Area Life Sciences News	Rebecca Zacks	03/26/10	Boston
Former Targanta CEO Leuchtenberger Lands New Gig at Rib-X, Another Antibiotic Company	Luke Timmerman	03/23/10	Boston
The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten	Luke Timmerman	10/08/09	Boston
Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test	Luke Timmerman	06/08/09	San Diego
Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections	Luke Timmerman	03/30/09	Seattle
Biotech Survival Index 2: Boston Life Sciences Companies Squirrel Away More Cash for Long Winter	Luke Timmerman	03/17/09	Boston
Novophage Forming to Combat Antibiotic Resistance with Engineered Viruses	Ryan McBride	03/05/09	Boston
Rib-X Raises $25M in Debt Financing, Reveals Final Results of Antibiotic Trial	Ryan McBride	01/26/09	Boston
$55M for Boston-Power, Sequenom Plows Ahead with Exact Sciences Takeover Attempt, Nuance Announces $175M Stock Sale, & More Boston-Area Deals News	Rebecca Zacks	01/16/09	Boston
Cubist and Alnylam Tackle RSV, Exact Sciences Fends Off Sequenom, An FDA Panel Backs GTC Biotherapeutics’ Goat-Milk Drug, & More Boston-Area Life Sciences News	Rebecca Zacks	01/14/09	Boston
Targanta Gets $42M Buyout Offer From NJ Drug Firm	Ryan McBride	01/13/09	Boston
New RNAi Drugs, Major Cutbacks at Targanta, Big Partnerships for Arqule and Archemix, & More Boston-Area Life Sciences News	Wade Roush	12/24/08	Boston
Genzyme and Boston Scientific Get Good News From the FDA; Acusphere and Targanta Not So Much; TransMedics Pulls IPO Plug; & More Boston-Area Life Sciences News	Rebecca Zacks	12/17/08	Boston
Targanta Faces New Challenges to Raise Cash After FDA Shoots Down the Firm’s Antibiotic	Ryan McBride	12/10/08	Boston
Novartis Deal Could Boost Ascent by $200M, Ariad’s Boardroom Drama Comes to Light, Targanta Takes Another Hit, & More Boston-Area Life Sciences News	Rebecca Zacks	12/10/08	Boston
New Biotechs and Other Tidbits from Mass Biotech Council Pitch Event	Ryan McBride	12/09/08	Boston
FDA Declines Approval of Targanta Antibiotic	Ryan McBride	12/09/08	Boston
Boston Biotechs Seek Scarce Funds Amid Market Famine at Annual Pitch Event	Ryan McBride	12/04/08	Boston
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter	Luke Timmerman	11/25/08	Boston
RXi Tackles RNAi Delivery, Pfizer Launches A Two-Cambridge Stem Cell Effort, Archemix Plows An Alternative Path to the Public Market, & More Boston-Area Life Sciences News	Rebecca Zacks	11/20/08	Boston
Targanta Antibiotic Shot Down By FDA Panel	Luke Timmerman	11/19/08	Boston
Targanta-Cubist Rivalry Brews on FDA Review of Targanta Drug	Ryan McBride	11/18/08	Boston
Sirtris Shifts Focus From Resveratrol, Merck Shifts People From Seattle to Boston, Epix Shifts Into Cost-Saving Mode, & More Boston-Area Life Sciences News	Rebecca Zacks	10/29/08	Boston
Targanta Releases Antibiotic Data	Ryan McBride	10/22/08	Boston
Trius Therapeutics, Developer of Antibiotic Against MRSA, Taking On Pfizer’s Zyvox	Luke Timmerman	10/20/08	San Diego
Biogen Idec Makes Controversial Tysabri Decision, Boston Scientific Explains Stock Sales, Charles River Heads to China, & More Boston-Area Life Sciences News	Rebecca Zacks	10/16/08	Boston
Sirtris Settles in at GSK, Alnylam Raises IP Questions on Bio Bill, Targanta Takes on Cubist’s Market, & More Life Sciences News	Rebecca Zacks	09/24/08	Boston
Biogen’s Busy Week, Alnylam’s Big Announcement, Targanta’s and Momenta’s Growing Executive Ranks, & More Life Sciences News	Rebecca Zacks	03/05/08	Boston
Page 1 of 2	next page »